These compounds were able to kill the patients’ Tregs isolated from ovarian cancer ascites more potently than those from healthy donors, supposedly due to the high TNFR2 expression on TME-infiltrating Tregs. This evidence concerns the gene TNFRSF1B and ovarian cancer.